PubRank

S Rockwell

Author PubWeight™ 85.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984 2.47
2 The sexual history in general medicine practice. Arch Intern Med 1984 2.42
3 Genetic instability induced by the tumor microenvironment. Cancer Res 1996 2.33
4 The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996 1.99
5 WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost 2010 1.69
6 Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993 1.52
7 In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy. Lab Anim Sci 1977 1.49
8 Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987 1.48
9 Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000 1.37
10 Repair of potentially lethal damage in vivo in solid tumor cells after x-irradiation. Cancer Res 1974 1.27
11 Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res 1973 1.25
12 The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 1980 1.24
13 Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999 1.22
14 Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res 1996 1.21
15 The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest 1999 1.16
16 Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 1994 1.13
17 Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998 1.10
18 Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984 1.07
19 Mitomycin C: a prototype bioreductive agent. Oncol Res 1994 1.06
20 Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J Med Chem 1999 1.04
21 Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980 1.03
22 Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res 1989 1.01
23 In vivo-in vitro tumour cell lines: characteristics and limitations as models for human cancer. Br J Cancer Suppl 1980 1.01
24 The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem 1998 1.00
25 A technique for determining the proportion of the clonogenic cells in S phase in ENT6 cell cultures and tumors. Cell Tissue Kinet 1976 0.99
26 IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 1996 0.97
27 Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci U S A 1996 0.96
28 Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997 0.94
29 Physical examination as a screening test for pelvic fractures in blunt trauma patients. W V Med J 1997 0.93
30 Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986 0.93
31 Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns. Cancer Res 1993 0.91
32 Genetic analysis of 2',3'-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem 1988 0.91
33 Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 1985 0.90
34 Evaluation of BA1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrophotometry, radiosensitivity, and magnetic resonance spectroscopy. Magn Reson Med 1991 0.90
35 Vitamin A inhibits radiation-induced pneumonitis in rats. J Nutr 1998 0.90
36 Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor. Int J Radiat Oncol Biol Phys 1985 0.89
37 Structure of adduct X, the last unknown of the six major DNA adducts of mitomycin C formed in EMT6 mouse mammary tumor cells. Chem Res Toxicol 2000 0.89
38 Biological basis of radiation sensitivity. Part 2: Cellular and molecular determinants of radiosensitivity. Oncology (Williston Park) 2000 0.89
39 Effect of host age on the transplantation, growth, and radiation response of EMT6 tumors. Cancer Res 1981 0.88
40 Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989 0.88
41 Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 2000 0.88
42 Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys 1985 0.87
43 Regulation of scatter factor production via a soluble inducing factor. J Cell Biol 1994 0.87
44 Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer 2000 0.87
45 Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer 2000 0.86
46 Iododeoxyuridine radiosensitization by low- and high-energy photons for brachytherapy dose rates. Radiat Res 1990 0.85
47 Formation of a major DNA adduct of the mitomycin metabolite 2,7-diaminomitosene in EMT6 mouse mammary tumor cells treated with mitomycin C. Oncol Res 1998 0.85
48 Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 1985 0.84
49 Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 1986 0.83
50 Applicability of animal tumor data to cancer therapy in humans. Int J Radiat Oncol Biol Phys 1988 0.83
51 Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis 1993 0.83
52 Growth and cell population kinetics of single and multiple KHT sarcomas. Cell Tissue Kinet 1972 0.83
53 Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells. Cancer Res 1987 0.82
54 Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul 1998 0.82
55 Effects of clumps and clusters on survival measurements with clonogenic assays. Cancer Res 1985 0.82
56 Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987 0.82
57 Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo. J Natl Cancer Inst 1983 0.81
58 Failure of 5-thio-D-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors. Radiat Res 1984 0.81
59 Fluosol and hyperbaric oxygen as an adjunct to radiation therapy in the treatment of malignant gliomas: a pilot study. Biomater Artif Cells Immobilization Biotechnol 1992 0.81
60 Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys 1982 0.81
61 Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 1979 0.80
62 Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem Pharmacol 1996 0.80
63 Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro. Int J Radiat Oncol Biol Phys 1982 0.80
64 Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int J Radiat Oncol Biol Phys 1986 0.80
65 Studies on the mechanism of the cytotoxic action of the mitomycin antibiotics in hypoxic and oxygenated EMT6 cells. Adv Enzyme Regul 1993 0.80
66 Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 2001 0.80
67 Magnetic resonance, pathology and physiology of the BA1112 rhabdomyosarcoma in vivo. Invest Radiol 1988 0.79
68 Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc Natl Acad Sci U S A 1999 0.78
69 Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. Cancer Commun 1991 0.78
70 Influence of a 1400-gauss magnetic field on the radiosensitivity and recovery of EMT6 cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1977 0.78
71 Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997 0.78
72 Cytotoxic and radiosensitizing effects of hypoxic cell sensitizers on EMT6 mouse mammary tumour cells in vivo and in vitro. Br J Cancer Suppl 1978 0.78
73 Cyclic radiation-induced variations in cellular radiosensitivity in a mouse mammary tumor. Radiat Res 1974 0.78
74 Enhancement of IUdR radiosensitization by low energy photons. Int J Radiat Oncol Biol Phys 1987 0.78
75 Enhanced IUdR radiosensitization by 241Am photons relative to 226Ra and 125I photons at 0.72 Gy/hr. Int J Radiat Oncol Biol Phys 1990 0.78
76 Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C. Adv Enzyme Regul 1985 0.78
77 Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol. Biochem Pharmacol 2001 0.78
78 An assay permitting quantitative comparison of tumor-directed immunity and tumor cell survival. J Natl Cancer Inst 1974 0.78
79 Effects of sodium pentobarbital on the radiation response of EMT6 cells in vitro and EMT6 tumors in vivo. Radiat Res 1980 0.77
80 Evaluation of 2-amino-5-nitrothiazole as a hypoxic cell radiosensitizer. Radiat Res 1982 0.77
81 Toxicity of intra-arterial mitomycin C to previously-irradiated tissues. Radiother Oncol 1986 0.77
82 Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicumarol on adduct patterns. Cancer Commun 1991 0.77
83 Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells. Cancer Commun 1991 0.77
84 Effectiveness and biological effects of techniques used to induce hypoxia in solid tumors. Radiother Oncol 1986 0.77
85 Quantitative transplantation assays of the rat rhabdomyosarcoma BA1112 isografts into the WAG/Rij Y rat and xenotransplantation into the athymic NCr (nu/nu) nude mouse. Eur J Cancer Clin Oncol 1989 0.77
86 Correlation between parental perception and actual childhood patterns of bicycle helmet use and riding practices: implications for designing injury prevention strategies. J Pediatr Surg 2001 0.76
87 Enhancement of artificial lung metastases by misonidazole. Int J Radiat Oncol Biol Phys 1984 0.76
88 Development of an in vitro assay for the survival of cells suspended from BA1112 rat sarcomas. Eur J Cancer Clin Oncol 1983 0.76
89 Inhibition of delayed hypersensitivity by metronidazole and misonidazole. Int J Radiat Oncol Biol Phys 1983 0.75
90 Combination therapy with misonidazole and mitomycin C: lack of chemosensitization of EMT6 tumor cells in vivo or in vitro. Int J Radiat Oncol Biol Phys 1984 0.75
91 A new potent radiosensitizer: 1-(2',3'-dideoxy-alpha-D-erythro-hex-2'-enopyranosyl)-2-nitroimidazole (RA-263). Int J Radiat Oncol Biol Phys 1982 0.75
92 Effect of 1-methyl-5-sulfonamide-4-nitroimidazole and 1-methyl-5-bromide-4-nitroimidazole on the radiosensitivity of EMT6 tumor cells. Cancer Treat Rep 1986 0.75
93 Effects of continuous low dose-rate irradiation: computer simulations. Cell Tissue Kinet 1988 0.75
94 Effect of a perfluorochemical emulsion on the development of artificial lung metastases in mice. Clin Exp Metastasis 1986 0.75
95 Effect of a perfluorochemical emulsion on the radiation response of BA1112 rhabdomyosarcomas. Radiat Res 1987 0.75
96 Hearing what cannot be seen: a psychoanalytic research group's inquiry into female sexuality. J Am Psychoanal Assoc 1996 0.75
97 Tumor size-dependent changes in a murine fibrosarcoma: use of in vivo 31P NMR for non-invasive evaluation of tumor metabolic status. Invest Radiol 1987 0.75
98 Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines. Oncol Res 1995 0.75
99 Relative biological effectiveness of 241Am relative to 192Ir for continuous low-dose-rate irradiation of BA1112 rat sarcomas. Radiat Res 1989 0.75
100 Cell proliferation in EMT6 tumours treated with single doses of X-rays or hydroxyurea. II. Computer simulations. Cell Tissue Kinet 1980 0.75
101 Distribution of porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice. J Natl Cancer Inst 1991 0.75
102 Effects of a perfluorochemical emulsion on the response of BA1112 rat rhabdomyosarcomas to continuous low-dose-rate irradiation. Radiat Res 1990 0.75
103 Development of a shielded 241Am applicator for continuous low dose rate irradiation of rat rectum. Int J Radiat Oncol Biol Phys 1992 0.75
104 Synthesis and evaluation of some nitrobenzenesulfonamides containing nitroisopropyl and (ureidooxy)methyl groups as novel hypoxic cell selective cytotoxic agents. J Med Chem 1991 0.75
105 Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263). Radiat Res 1986 0.75
106 Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin. Adv Enzyme Regul 1995 0.75
107 Tumor-to-tumor variability in the hypoxic fractions of experimental rodent tumors. Radiother Oncol 1984 0.75
108 Absence of contact effects in irradiated EMT6-Rw tumors. Radiat Res 1986 0.75
109 Immunosuppression by hypoxic cell radiosensitizers: a phenomenon of potential clinical importance. Int J Radiat Oncol Biol Phys 1982 0.75
110 Development of an 241Am applicator for continuous low-dose-rate irradiation of the rat sarcoma BA1112. Int J Radiat Oncol Biol Phys 1987 0.75
111 Suppression of cell-mediated immunity by misonidazole. Int J Radiat Biol Relat Stud Phys Chem Med 1982 0.75
112 Cell proliferation in EMT6 tumors treated with single doses of x-rays or hydroxyurea. I. Experimental results. Cell Tissue Kinet 1978 0.75
113 The riddle of femininity: the interplay of primary femininity and the castration complex in analytic listening. Int J Psychoanal 2001 0.75
114 Soft-tissue sarcomas: detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 1990 0.75
115 Biological basis of radiation sensitivity. Part 1: Factors governing radiation tolerance. Oncology (Williston Park) 2000 0.75
116 A mathematical model for analysing cellular age-response functions in terms of physiological age. Cell Tissue Kinet 1981 0.75